Laura A. VanBlargan

Laura A. VanBlargan

Auto-generated profile, based on publicly available information

Laura A. VanBlargan

Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Nature
Verified
Journal Article
Closed access
ECElisabetta Cameroni
Elisabetta Cameroni
JBJohn E. Bowen
John E. Bowen
LRLaura E. Rosen
Laura E. Rosen
CSChristian Saliba
Christian Saliba
SZSamantha K. Zepeda
Samantha K. Zepeda
DCDavide Corti
Davide Corti

19 January 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LVLaura A. VanBlargan
Laura A. VanBlargan
JEJohn M. Errico
John M. Errico
PHPeter J. Halfmann
Peter J. Halfmann
SZSeth J. Zost
Seth J. Zost
JCJames E. Crowe
James E. Crowe
MDMichael Diamond
Michael Diamond

31 March 2022 in Nature
Verified
Journal Article
Closed access
PDF file
MDMarciela M. DeGrace
Marciela M. DeGrace
EGElodie Ghedin
Elodie Ghedin
Matthew FriemanMatthew Frieman
Matthew Frieman
Florian KrammerFlorian Krammer
Florian Krammer
AGAlba Grifoni
Alba Grifoni
MSMehul Suthar
Mehul Suthar

25 May 2022 in Science Translational Medicine
Verified
Journal Article
Open access
AHAndrew C. Hunt
Andrew C. Hunt
JCJames Brett Case
James Brett Case
YPYoung-Jun Park
Young-Jun Park
LCLongxing Cao
Longxing Cao
KWKejia Wu
Kejia Wu
DBDavid Baker
David Baker
New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a cell-free expression workflow to rapidly screen and optimize constructs containing multiple computationally designed miniprotein inhibitors of SARS-CoV-2. We found the broadest efficacy was achieved with a homotrimeric version of the 75-residue angiotensin-converting enzyme 2 (ACE2) mimic AHB2 (TRI2-2) designed to geometrically match the trimeric spike architecture. Consistent with the design model, in the cryo-electron microscopy structure TRI2-2 forms a tripod at the apex of the spike protein that engaged all three receptor binding domains simultaneously. TRI2-2 neutralized Omicron (B.1.1.529), Delta (B.1.617.2), and all other variants tested with greater potency than the monoclonal antibodies used clinically for the treatment of COVID-19. TRI2-2 also conferred prophylactic and therapeutic protection against SARS-CoV-2 challenge when administered intranasally in mice. Designed miniprotein receptor mimics geometrically arrayed to match pathogen receptor binding sites could be a widely applicable antiviral therapeutic strategy with advantages over antibodies in greater resistance to viral escape and antigenic drift, and advantages over native receptor traps in lower chances of autoimmune responses.

1 October 2021 in Immunity
Verified
Journal Article
Closed access
LVLaura A. VanBlargan
Laura A. VanBlargan
LALucas J. Adams
Lucas J. Adams
ZLZhuoming Liu
Zhuoming Liu
RCRita E. Chen
Rita E. Chen
PGPavlo Gilchuk
Pavlo Gilchuk
MDMichael Diamond
Michael Diamond

2 February 2022 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
BYBaoling Ying
Baoling Ying
BWBradley Whitener
Bradley Whitener
LVLaura A. VanBlargan
Laura A. VanBlargan
AHAhmed O. Hassan
Ahmed O. Hassan
SSSwathi Shrihari
Swathi Shrihari
MDMichael Diamond
Michael Diamond
Although mRNA vaccines encoding the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevent COVID-19, the emergence of new viral variants jeopardizes their efficacy. Here, we assessed the immunogenicity and protective activity of historical (mRNA-1273, designed for Wuhan-1 spike protein) or modified (mRNA-1273.351, designed for B.1.351 spike protein) Moderna mRNA vaccines in 129S2 and K18-hACE2 mice. Mice were immunized with either high-dose or low-dose formulations of the mRNA vaccines, where low-dose vaccination modeled suboptimal immune responses. Immunization with formulations at either dose induced neutralizing antibodies in serum against ancestral SARS-CoV-2 WA1/2020 and several virus variants, although serum titers were lower against the B.1.617.2 (Delta) virus. Protection against weight loss and lung pathology was observed with all high-dose vaccines against all viruses. However, low-dose formulations of the vaccines, which produced lower magnitude antibody and T cell responses, showed breakthrough lung infections with B.1.617.2 and development of pneumonia in K18-hACE2 mice. Thus, in individuals with reduced immunity after mRNA vaccination, breakthrough infection and disease may occur with some SARS-CoV-2 variants.